ENTA News and Press, Enanta Pharmaceuticals Inc. From 11/05/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Investors hungry for stocks that can make big moves in a short amount of time know the biotech industry is the best place to look. A new drug approval, or simply clinical trial results that suggest success can push small-cap stocks through the roof. Recently, Cara Therapeutics ...

- Demonstrated Highly Potent Antiviral Activity Against SARS-CoV-2 in Cellular Models - - Once-Daily, Oral Dosing Supported by Optimized Pharmacokinetic Properties - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to c...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral protease inhibitor specifically designed for the tr...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat on W...

– EDP-305 1.0 mg Selected as Optimal Dose Following ARGON-2 Interim Analysis – – EDP-297 Not Substantially Differentiated from EDP-305 Based on Recent Phase 1 Results – – Company to Discontinue ARGON-2 Trial Evaluating EDP-305 as a Mo...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the company will have two poster presentations showcasing clinical data for EDP-514, a novel pange...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investo...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the election of Yujiro S. Hata, to its Board of Directors. This press release features multimedia. V...

- Initial Data Expected in the First Half of 2022 - Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first su...